Is Jupiter Neurosciences going out of business?

JUPITER NEUROSCIENCES, INC. (JUNS) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

JUPITER NEUROSCIENCES, INC. (JUNS) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Critical

Runway cannot be estimated from the available cash and cash-flow fields. Debt pressure is the other decisive risk.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (6.2% YoY) and the capital-structure risk is penalized.
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Interest coverage: -24.3x
• Return on Assets: -232.48%
• Price / Sales: 190.6x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -50718.6%

Read from filings through 2026-08-14.

Price as of 2026-09-09.